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Purpose or Objective: Many patients with advanced cancer 
develop bone metastases, with pain as a common, 
devastating consequence. Adequate treatment is important 
to maintain quality of life. Radiotherapy is the standard 
treatment for patients with painful bone metastases. Meta-
analyses of radiotherapy trials have consistently shown a pain 
response rate of approximately 60% implying that many 
patients are treated insufficiently. It would be worthwhile to 
identify patients who will not respond to radiotherapy as 
these patients might be candidates for other treatments. 
Furthermore, better understanding and identification of the 
patients who do not respond to radiation, might help in the 
development of innovative treatments as alternative or 
addition to standard (radiation) treatment options. We 
studied the relationship between patient and treatment 
characteristics and pain response in patients with metastatic 
bone disease, with the aim to construct a prediction model to 
guide individualized treatment decision-making. 
 
Material and Methods: We analyzed all prospectively 
collected data on pain response from a palliative 
radiotherapy clinic in an academic hospital. Patients were 
considered responders if they reported a decrease in pain 
score of at least 2 points with stable analgesic use within 3 
months after treatment. A multivariable logistic regression 
model was developed with age, gender, primary tumor, 
Karnofsky performance status (KPS), painful localization, 
presence of visceral metastases, previous systemic 
treatment, analgesic use at baseline, and baseline pain 
score. For variable selection, we started with the full model 
and applied backward stepwise selection with a selection 
criterion of p < 0.20. Performance of the model was 
quantified using the c-statistic and corrected for optimism. A 
worst case scenario (assuming no response in patients who 
were lost to follow up) was added as sensitivity analysis. 
 
Results: A total of 1018 patients treated between January 
1999 and November 2007 were included. Outcome was 
recorded in 588 (58%) patients, of which 394 (67%) reported a 
response. Primary tumor, KPS, baseline pain score, and 
analgesic use were predictive for response with a corrected 
c-statistic of 0.59 (Table). Assuming non-response in the 430 
patients without follow up (worst case scenario), there was 
still an association between response and primary tumor, 
KPS, and baseline pain score. 
 
Conclusion: Primary tumor, performance status, baseline 
pain score, and analgesic use are associated with pain 
response in patients with bone metastases. However, 
combining these factors in a prediction model showed poor 
discrimination limiting its use in clinical practice. Response 
rates after radiotherapy are moderate, and its prediction is 
difficult, which shows the need for development of 
innovative treatments for patients with bone metastases. 
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Purpose or Objective: To present the observed comparative 
advantages of the single fraction versus long course radiation 
therapy in the palliative treatment of bone metastasis, in the 
conditions of technological resources limited to one national 
center equipped with only cobalt machines.Purpose: To 
present the observed comparative advantages of the single 
fraction versus long course radiation therapy in the palliative 
treatment of bone metastasis, in the conditions of 
technological resources limited to one national center 
equipped with only cobalt machines. 
Material and Methods: The Radiation Therapy of Mother 
Theresa University Hospital Center, the unique public center 
providing RT in the country, performed a study comparing 
single dose of 8 Gy/1fr. versus 20 Gy/5fr. and 30gy/10fr. 
enrolling 110 patients during a time period of five years (2007 
– 2012). Factors for the treatment choice between available 
options were age, pain level, effect of narcotics and need for 
assistance as well as time and cost effectiveness. Pain relief 
was assessed based on the patient perception expressed 
during the follow up visits, 2 weeks, 4 weeks and 12 weeks 
after the treatment and subsequently every 12 weeks for a 
period of 48 weeks. Qualitative data from the follow up visits 
were classified in a scale of 10 points. 
 
Results: The complete pain relief was attained for 90 
patients or 81.8% out of 110 patients, subject to this study. 
From this number, 33 patients were treated with single shot, 
31 with 20 Gy/5 fraction and 46 with 30Gy/10fr. The 
percentage of patients benefiting partial pain relief varied 
from 17.4 to 19.5 which indicate also similar results from the 
available treatment regimes. Therefore, it wasn’t evidenced 
significant difference between the treatment options as 
regard to the patients achieving complete or partial pain 
relief. Further, the toxicity level scored 2-3 grade for all the 
treatment regimes used. In addition, the patients 
demonstrated similar median survival from 8 to 10 months for 
the three options. 
 
Conclusion: The findings of the study indicate that single 
fraction 800cGy/1fr is a treatment option with similar effects 
with the multiple fractions 20Gy/5fr and 30Gy/10fr. It can be 
used as more time and cost effective standard treatment 
especially for patients presenting higher level of pain and 
more in need for assistance including elder and those more 
distant from the treatment centers. 
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Purpose or Objective: To assess the efficacy of a SHort-
course Accelerated RadiatiON therapy (SHARON) regimen in 
the palliative treatment of complicated bone metastases. 
ESTRO 35 2016                                                                                                                                                    S667 
________________________________________________________________________________ 
Material and Methods: A phase II clinical trial was planned 
based on optimal two-stage Simon’s design. Eligibility criteria 
included patients with an Eastern Cooperative Oncology 
Group (ECOG) performance status of ≤3. The primary 
endpoint was to evaluate the symptoms response rate 
produced by a radiotherapy regimen based on the delivery of 
4 radiotherapy fractions (5 Gy per fraction) with a twice daily 
fractionation in two consecutive days. 
 
Results: Twenty-nine patients were enrolled in this trial. 
Characteristics of the patients were: male/female: 16/13; 
median age: 66 years (range: 46-87). ECOG performance 
status was <3 in 25 patients (86.2%). With a median follow-up 
time of 5.0 months (range, 1 to 36 months), 9 G1-2 gastro-
intestinal (31%), 2 G1 haematological (6.8%) and 6 G1 skin 
(20.7%) toxicities were recorded. Only 1 patient (3.4%) 
experienced G3 acute gastro-intestinal toxicity. Of 29 
symptomatic patients, 27 showed an improvement or 
resolution of baseline symptoms (overall palliative response 
rate: 92.6%). Three-month overall survival was 92.2% (median 
survival time: not reached). In 25 patients with pain, a 
significant reduction of this symptom was recorded in terms 
of Drug Score (mean baseline Drug Score vs mean Drug Score 
at follow-up: 5.3 vs 4.0; p=0.04).  
 
Conclusion: Short-course accelerated radiotherapy on 
complicated bone metastases (20 Gy in twice daily fractions 
for 2 consecutive days) is tolerated and effective in terms of 
symptom relief. A phase III comparison against a standard 
palliative regimen (30 Gy in 10 fractions) has been planned in 
this patient population. 
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Purpose or Objective: More than 90% of patients with 
metastatic castration resistant prostate cancer (CRPC) have 
radiologic evidence of bone metastases. Radium-223 
dichloride therapy showed improved overall survival, quality 
of life and symptom control in patients with symptomatic 
bone metastases. Aim of the present study is to evaluate 
clinical course of patients treated in our centre including 
biochemical and imaging response.  
 
Material and Methods: Since November 2014 we started the 
treatment of symptomatic bone metastatic CRPC patients 
with Radium-223 dichloride (50kBq/kg, every 4 weeks). 
Before and after every administration the following 
parameter were recorded: PSA and alkaline phosphatase 
(ALP) values, pain numerical rating scale (NRS), performance 
status (ECOG scale), analgesic therapy and side effects 
(graded according to the CTCAE v. 4 classification). A whole 
body scintigraphy was performed before and one month after 
the treatment.  
 
Results: Twenty patients (total: 70 administrations) were 
treated. All patients showed increased PSA value and reduced 
ALP values. Performance status, evaluated with ECOG scale, 
was improved in all patients. Pain control was excellent, with 
reduction of NRS and analgesic therapies in all patients. Most 
patients showed only G1 toxicity: anaemia (15 pts), fatigue (3 
pts), diarrhea (1 pt), nausea (1 pt), and pain flare-up (6 pts). 
Eight patients completed the 6 planned cycles of therapy. Six 
patients discontinued treatment due to adverse events: 
anaemia (2 pts), pathological fracture of the femur (1 pt), 
severe bleeding (2 pts) and complications in uncontrolled 
diabetes (1 pt). The other patients are still under treatment. 
Whole body scintigraphy performed one month after the end 
of the treatment demonstrated in all patients a reduced 
intensity and number of uptake areas without correlation 
with PSA values. 
 
Conclusion: Treatment with Radium 223 in patients with 
CRPC and symptomatic bone metastases was tolerated in the 
majority of patients. High response rates in terms of 
symptom control and QoL improvement were recorded. 
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Purpose or Objective: To determine the results of 55 
patients with Superior Vena Cava Syndrome (SVCS) treated 
with radiotherapy. 
 
Material and Methods: Between September 2009 and 
September 2014, 55 patients with SVCS were treated at 
Operative Unity of Radiotherapy and Radiobiology, “Hospital 
Pugliese-Ciaccio”, Catanzaro. Of these 21 were women and 
34 men, with a median age at diagnosis of 61 years (range 33-
77 years).The most predominant symptoms were face or neck 
swelling (85%), upper swelling extremity (73%), dyspnea 
(70%), cough (62%), neck and vein distension (45%). 
Radiotherapy (RT) has been the only treatment in 6 of 11 
patients in which the rapidly progressive symptoms has not 
allowed to submit to a histologic diagnosis. For the patients 
which the histo-pathological diagnosis was known and for 
those in which to effect it, the treatment has included both 
the chemotherapy and the radiotherapy. The fractionation 
schedule usually has included initial fractions of 300-400 cGy 
(2-4 fractions) followed by conventional fractionation of 180-
200 cGy. The RT total dose delivered is varied by 2000 cGy to 
5000 cGy 
 
Results: With regard radiotherapy delivered, in 5 (9%) of the 
55 patient essays we have observed a complete regression of 
the SVCS, while in 27 (49%) the response has been partial, 
stability of illness has been underlined in 15 (27%) patients 
and disease progression in 8 (15%) patients. 
 
Conclusion: In summary, in the SVCS the clinical symptoms 
often requires an urgent intervention. Survival depend on the 
status of patient’s disease and on the histologic type of the 
tumor. Radiotherapy is effective in the treatment of the 
initial SVCS and in the patients that relapsed or with 
recurrent illness. The radiotherapy produces a good control 
of the symptoms. There is no necessity of ample fractions in 
the initial treatment. In the reirradiation, the radiotherapy 
on mediastinum is one of the most greater components of the 
palliation. Moreover, in presence laryngeal stridor the 
radiotherapy can be administered before the histological 
diagnosis is available. 
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